3M completes acquisition of Futuro health hosiery line
ST. PAUL, Minn. 3M on Tuesday announced that it has completed its acquisition of the Futuro health supports and compression hosiery product line from Beiersdorf.
Terms of the transaction were not disclosed.
The acquisition marries two venerable brands in the first aid/sports support products space. Futuro’s complete line of therapeutic and sport supports—wraps, braces and elastic bandages—provide compression support and heat retention as well as stability to relieve symptoms associated with minor sprains, strains, arthritis and muscle pain.
Futuro’s compression hosiery products include therapeutic and anti-embolism stockings. Futuro health supports and Futuro compression hosiery products are sold through consumer channels, including drug stores, mass merchandisers and grocers in North America, and pharmacies internationally.
And 3M already has a number of high-performance products under its Nexcare brand to help people heal—from braces for the knee, wrist, ankle and back, to products for after surgery care, skin care and athletic wraps under its broad line of Nexcare branded bandage and first aid products.
Female Health announces approvals for marketing its second-generation female condom
CHICAGO The Female Health Company on Friday announced that the Food and Drug Administration’s Obstetrics and Gynecology Devices Advisory Committee unanimously voted that the company’s second-generation female condom, the FC2 Female Condom, is approvable for sale over-the-counter provided that the FC2 Female Condom’s instructions for use continue to follow use instructions for the FC Female Condom and identify the study that was performed to establish the comparable safety and effectiveness of FC2 with FC1.
“We are very pleased with today’s outcome and look forward to working with the FDA as it continues to review our application for the FC2 Female Condom,” said Mary Ann Leeper, FHC’s Senior Strategic Advisor. “We believe that FHC’s second-generation female condom can strengthen the fight against AIDS by expanding affordable access to a woman-initiated HIV prevention method.”
The FC2 Female Condom, which looks very similar to the FC1 Female Condom, was developed to expand access to women at risk of HIV and STIs by lowering the cost of the product through the introduction of a more efficient manufacturing process.
The company’s first-generation FC1 Female Condom received FDA approval for distribution in the United States in 1993.
The FDA is not bound by the committee’s recommendation, but it takes its advice into consideration when reviewing obstetric and gynecologic devices.
DreamPak launches appetite control snack Trimma
ALEXANDRIA, Va. DreamPak Nutritional Supplements on Monday launched its appetite and weight control snack called Trimma, which contains natural appetite-reducing ingredients, the company stated.
According to the company, Trimma chocolate soft chews contain two clinically-tested ingredients, PinnoThin and Slendesta. PinnoThin stimulates the production of hunger-eliminating hormones in the body, signaling feelings of fullness to the brain. Slendesta enhances and extends the release of hunger-eliminating hormones.
“Trimma works to reduce food cravings and satisfy hunger,” said Waleed Gamay, account manager of DreamPak. “We’ve seen a shift in consumers’ attitudes toward diet as well as health and wellness, with more consumers seeking product choices that support active lifestyles.”